6.2.1 CEO 2022 STI Achievement and Outcome The Board considered the following highlights when determining the STI outcome for Mr Perreault. Table 4: CEO STI Outcomes in 2022 Measure and Commentary Weight Threshold 50% Target 100% Maximum 200% % of Maximum Opportunity Financials • Solid adjusted NPAT result against target 35% US$2,125m US$2,361m US$2,597m 47.5% • Strong adjusted CFO outcome exceeding target 25% US$2,028m US$2,253m US$2,591m 96.5% Stabilise plasma business fundamentals and return to sustainable growth • Plasma collection improvement on 2021 • US regulatory clearance received for the new plasmapheresis platform and progression of the partnership with Terumo – delay of implementation due to supply chain constraints • Transformation of an integrated global R&D function across CSL and Seqirus • Execution of merger and acquisition deals with significant achievement on the Vifor acquisition 20% 65.0% Deliver growth and efficiency initiatives and build a robust pipeline of safe and effective life-saving medicines • Above target outcomes on IG roadmap • Improvement in all safety metrics over prior year – TRIFR improvement across most functions/sites • Readiness for new product launches across the end to end supply chain and commercial operations • Significant progress on the sustainability strategy and roadmap • Lengnau mechanical completion and transition to Thermo Fisher Scientific management 10% 87.5% People and Culture • Key succession plan milestones advanced • Diversity, Equity and Inclusion objectives delivered ensuring trending toward achievement of longer term goals 10% 75.0% CSL Limited Annual Report 2021/22 83
RkJQdWJsaXNoZXIy MjE2NDg3